Biogen Message Board - Msg: 10090881

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 172.50

-2.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Partmann who wrote (1026)	6/12/1999 12:12:00 AM
From: P.M.Freedman	Read Replies (1) of 1686

Bill--Do you know that two chemokines and two receptors have been found to be involved in multiple sclerosis recently. This finding suggests that MS could be treated by blocking the cell receptors for those molecules, similar to treatments currently being developed for diseases as diverse as asthma and AIDS. This means some new small molecule oral drugs with better bioavailabilities for treatment of MS will come soon. Drugs like Avonex with huge molecular weight and lower bioavailability may face serious competitions. I don't think Avonex will be good for long term investment. The key things for Biogen is to build up it's new product pipeline like IMNX did.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next